In conclusion, we have proven that melanoma cells in vivo are sensitive to the anti-tumor effects of HDAC inhibitors, an effect that can be enhanced by the multi-kinase and chaperone inhibitor pazopanib. This evidence concerns the gene HDAC9 and melanoma.